A new experimental treatment is offering significant hope for children and families grappling with Dravet syndrome, a rare and devastating form of epilepsy. Results from an international clinical trial, led by University College London (UCL) and Great Ormond Street Hospital (GOSH), show the investigational drug zorevunersen can dramatically reduce seizure frequency – by as much as 91 percent – and may improve cognitive and behavioral outcomes. The findings, published in The New England Journal of Medicine, represent a potential turning point for a condition that has historically proven resistant to treatment.
Dravet syndrome, affecting approximately one in 15,000 births in the UK, typically begins in the first year of life with prolonged seizures often triggered by fever. As children grow, seizures become more frequent and difficult to control, leading to developmental delays, movement problems and an increased risk of premature death. Existing medications often provide limited relief, and no currently approved therapies address the cognitive and behavioral challenges associated with the disorder. This new research focuses on tackling the root cause of the disease – a faulty gene – rather than simply managing the symptoms.
Zorevunersen, developed by Stoke Therapeutics in collaboration with Biogen, works by targeting the SCN1A gene. Most people have two copies of this gene, which provides instructions for making a protein essential for proper nerve cell function. In individuals with Dravet syndrome, one copy of the SCN1A gene is often defective, leading to insufficient protein production. The drug aims to increase the levels of this crucial protein from the healthy gene copy, restoring more normal nerve cell activity.
The clinical trial involved 81 children with Dravet syndrome, aged between two and 18, from the United Kingdom and the United States. Participants received varying doses of zorevunersen, administered via lumbar puncture. Before treatment, the children experienced an average of 17 seizures each month. Researchers monitored seizure frequency, cognitive function, behavior, and overall quality of life. Notably, 75 of the children continued into extension studies, receiving the medication every four months.
Among those receiving a 70mg dose during the initial phase, seizure frequency decreased by 59 to 91 percent during the first 20 months of the extension studies, compared to their seizure rates before treatment began. Beyond seizure reduction, the study also offered early indications that zorevunersen may positively impact cognitive and behavioral aspects of the condition, with children showing improvements in quality of life over a three-year period. Importantly, most reported side effects were mild.
Understanding the Impact on Families
The potential impact of zorevunersen extends far beyond seizure statistics. For families living with Dravet syndrome, the constant fear of seizures and the associated developmental challenges create immense emotional and practical burdens. Lauren Truelove, mother of eight-year-vintage Freddie, who participated in the trial at Sheffield Children’s NHS Foundation Trust, described the treatment as “completely changed” their lives. Before zorevunersen, Freddie experienced numerous seizures nightly. After starting the treatment in 2021, his seizures were reduced to just one or two brief episodes every three to five days. “We now have a life we didn’t ever think was possible and most importantly it’s a life that Freddie can enjoy,” she said.
How the Trial Was Conducted
The trial was a collaborative effort involving multiple hospitals in the UK, including Great Ormond Street Hospital, Sheffield Children’s Hospital, Evelina London Children’s Hospital, and The Royal Hospital for Children in Glasgow. At GOSH, the study took place at the National Institute of Health and Care Research’s Clinical Research Facility, a specialized center for pediatric clinical trials. Participants received doses of up to 70mg of zorevunersen through a lumbar puncture, with some receiving a single dose and others receiving additional doses over a six-month period.
Professor Helen Cross, Director and Professor of Childhood Epilepsy at the UCL Institute of Child Health and an Honorary Consultant in Paediatric Neurology at GOSH, emphasized the significance of the findings. “I regularly see patients with hard-to-treat genetic epilepsies with impacts that go beyond seizures and it’s heart-breaking when treatment options are limited,” she said. “This new treatment could help children with Dravet syndrome lead much healthier and happier lives.” She added that the drug appeared safe and well-tolerated by most patients, supporting further evaluation in the ongoing Phase Three study.
What’s Next for Zorevunersen?
While the initial trial results are promising, zorevunersen is not yet approved for widespread use. A larger Phase Three clinical trial is currently underway to further evaluate the drug’s efficacy and safety. Galia Wilson, Chair of Trustees at Dravet Syndrome UK, expressed cautious optimism. “We’re now looking forward to the Phase Three clinical trials taking place to see if the early promise we see here will translate into real hope for all those families currently affected by Dravet Syndrome.”
The ongoing Phase Three trial will be crucial in determining whether zorevunersen can become a standard treatment option for children with Dravet syndrome. Families and medical professionals alike are eagerly awaiting the results, which could offer a life-changing opportunity for those affected by this challenging condition. For more information about Dravet syndrome and ongoing research, visit the Dravet Syndrome Foundation website.
Disclaimer: This article provides information for general knowledge and informational purposes only, and does not constitute medical advice. This proves essential to consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
Share your thoughts and experiences in the comments below. If you found this article helpful, please share it with your network.
